The economic calendar is packed full of potential market-moving events, most notably Friday morning's release of the March jobs report. Wall Street won't have to wait long to hear what the Federal ...
Shares in US-based Clovis Oncology have ticked up after the biotech became the first to get a PARP class drug approved in prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback